ASCO 2020

Area: Oncology

Location: Online, Virtual

Date: May 29 to May 31


Search in Scientific Content:
Date
Filters:
KEYNOTE-20
7:11

KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab versus brentuximab vedotin in relapsed or refractory classic Hodgkin lymphoma

Presenter: John Kuruvilla
Oncology
Update on
14:57

Update on state-of-the-art therapy in lung cancer

Presenter: Solange Peters
Oncology
GU cancer
12:02

GU cancer highlights of ASCO 2020

Presenter: Ignacio Duran
Oncology
Melanoma h
19:40

Melanoma highlights of ASCO 2020

Presenter: Michael A. Postow
Oncology
Osimertini...
8:15

Osimertinib as adjuvant therapy in patients with stage IB–IIIA EGFR mutation positive NSCLC after complete tumor resection: ADAURA

Presenter: David R. Spigel
Oncology
Trifluridi...
9:28

Trifluridine/tipiracil or regorafenib in refractory metastatic colorectal cancer patients: An AGEO prospective “real life” study

Presenter: Clélia Coutzac
Oncology
Highlights
20:32

Highlights of ASCO

Presenter: Jeffrey Weber
Oncology
First safe
8:49

First safety and efficacy results of PRADO: A phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in resectable stage III melanoma

Presenter: Irene Reijers
Oncology
Maintenanc
10:18

Maintenance avelumab + best supportive care versus BSC alone after platinum-based first-line chemotherapy in advanced urothelial carcinoma: JAVELIN Bladder 100 phase III interim analysis

Presenter: Elizabeth R. Plimack
Oncology
Carfilzomi
4:22

Carfilzomib, lenalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone for initial therapy of newly diagnosed multiple myeloma: Results of ENDURANCE phase III trial

Presenter: Shaji Kumar
Oncology
Updated re
3:13

Updated results from BELLINI, a phase III study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma

Presenter: Shaji Kumar
Oncology
Pembrolizu
3:56

Pembrolizumab Versus Chemotherapy for Microsatellite Instability-High/Mismatch Repair Deficient Metastatic Colorectal Cancer: The Phase 3 KEYNOTE-177 Study

Presenter: Thierry Andre
Oncology
Immune che
7:58

Immune checkpoint inhibitor therapy in colorectal cancer

Presenter: Thierry Andre
Oncology

ASCO 2017

2017-06-02 - 2017-06-06
Chicago, United States

SABCS 2016

2016-12-06 - 2016-12-10
San Antonio, United States

ESMO 2016

2016-10-07 - 2016-10-11
Copenhagen, Denmark

ASCO 2016

2016-06-03 - 2016-06-07
Chicago, United States

ELCC 2016

2016-04-13 - 2016-04-16
Geneva, Switzerland

ESMO ECCO 2015

2015-09-25 - 2015-09-29
Vienna, Austria

ASCO 2015

2015-05-29 - 2015-06-02
Chicago, United States

ELCC 2015

2015-04-15 - 2015-04-18
Geneva, Switzerland

Bratislava 2014

2014-10-09 - 2014-10-10
Bratislava, Slovakia